Novacyt: Monthly review of the liquidity contract and voting rights

Novacyt SA, an international specialist in molecular diagnostics, has published the monthly results of its liquidity contract, managed by Invest Securities SA. From March 1 to 31, 2025, 32,389 shares were purchased, while 17,611 were sold. The transactions were carried out at prices ranging from €0.49 to €0.61. At the close of trading on March 31, 2025, the company held 87,900 treasury shares.

Novacyt's total number of ordinary shares is 70,626,248. This figure, which is crucial for shareholders, serves as the denominator for assessing their holdings in accordance with the French Commercial Code. The company is not subject to the Financial Conduct Authority's financial transparency guidelines.